Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Live Attenuated Varicella Vaccine in Healthy People
NCT05669625Phase 3Active, not recruiting
- Sponsor
- China National Biotec Group
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varicella vaccine live in varicella (VZV) (2 arms), sponsored by China National Biotec Group. Primary endpoints: The incidences of varicella in each group and The efficacy of the live attenuated varicella vaccine. Started Dec 2022; status: active, not recruiting.
02
Drugs
varicella vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT05669625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669625.